Kidney Cancer

Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer

Publish Date March 17, 2023

Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma

Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC

Publish Date March 15, 2023

Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.

Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC

Publish Date March 14, 2023

In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.

RCC Stratification System May Need to Be Refined, Data Suggest

Publish Date March 13, 2023

Investigators conclude that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.

Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates

Publish Date March 13, 2023

Findings may inform treatment decisions after nephrectomy with positive surgical margins.

Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations

Publish Date March 9, 2023

Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.

Age Is a Risk Factor for Kidney Function Decline After Radical Nephrectomy

Publish Date February 22, 2023

Nephron-sparing management is one strategy to reduce risks, according to investigators.

Systemic Therapy Does Not Worsen Cytoreductive Nephrectomy Outcomes

Publish Date February 21, 2023

Management of metastatic renal cell carcinoma should be highly individualized, according to investigators.

Opioid Prescription Can Be Eliminated After Urologic Cancer Surgery

Publish Date February 16, 2023

Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, and opioid misuse, investigators noted.

Adjuvant ICI Therapy Provides DFS Benefit in Certain Patients With RCC

Publish Date February 14, 2023

Certain patients with resected renal cell carcinoma may benefit from adjuvant treatment with immune checkpoint inhibitors, a meta-analysis suggests.